Epigenetic regulation of protein translation in KMT2A-rearranged AML

Rearrangements of KMT2A (MLL1) occur in 10% of persons with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and in 70% of cases of infant ALL. With few exceptions, KMT2A rearrangements are associated with a poor prognosis, and KMT2A-rearranged (KMT2A-r) leukemias have been the target of substantial drug development efforts and clinical research without much impact yet on survival [1]. KMT2A fusions are strongly transforming [2], likely because of the profound epigenetic changes they induce.

Source: Experimental Hematology - May 9, 2020 Category: Hematology Authors: Alexandra Lenard, Hongbo Michael Xie, Taylor Pastuer, Tyler Shank, Clara Libbrecht, Molly Kingsley, Simone S. Riedel, Zuo-Fei Yuan, Nan Zhu, Tobias Neff, Kathrin M. Bernt Tags: Regular Submission Source Type: research